PMS-OLMESARTAN-HCTZ TABLET

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

Commercializzato da:

PHARMASCIENCE INC

Codice ATC:

C09DA08

INN (Nome Internazionale):

OLMESARTAN MEDOXOMIL AND DIURETICS

Dosaggio:

25MG; 40MG

Forma farmaceutica:

TABLET

Composizione:

HYDROCHLOROTHIAZIDE 25MG; OLMESARTAN MEDOXOMIL 40MG

Via di somministrazione:

ORAL

Confezione:

30/100/1000

Tipo di ricetta:

Prescription

Area terapeutica:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Dettagli prodotto:

Active ingredient group (AIG) number: 0252502003; AHFS:

Stato dell'autorizzazione:

CANCELLED PRE MARKET

Data dell'autorizzazione:

2019-02-07

Scheda tecnica

PRODUCT MONOGRAPH
Pr
PMS-OLMESARTAN-HCTZ
Olmesartan Medoxomil and Hydrochlorothiazide Tablets
20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg
Angiotensin II AT
1
Receptor Blocker - Diuretic
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Quebec
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
June 28, 2017
Submission Control No.: 205707, 200930
_ _
_pms-OLMESARTAN-HCTZ Product Monograph _
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
...............................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
CLINICAL TRIALS
.....................................................................